Here is a rundown of what you and your colleagues found to be most interesting in the field of diagnostic and interventional cardiology during the month of December.

1. Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat Atrial Fibrillation



The Diagnostic and Interventional Cardiology (DAIC) team wish you a happy, healthy and prosperous New Year!


December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent

December 27, 2023 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, and

December 27, 2023 — Butterfly Network, Inc., a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, and 

December 26, 2023 — Globally esteemed cardiologist and researcher, Harlan M. Krumholz, MD, SM, FACC, has been named editor-in-chief of the Journal of the American College of Cardiology, the nation’s leading source of clinical research in the field of cardiovascular medicine and the flagship journal of the American College of Cardiology.

December 26, 2023 — MindMics, Inc. reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR).

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.


The Diagnostic and Interventional Cardiology (DAIC) team wishes you a very happy holiday season and prosperous New Year!


Subscribe Now